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Biofilm accounts for 65%-80% of microbial infections in humans. Considerable evidence 
links biofilm formation to oral disease and consequently systemic infections. Eradication of biofilm-
associated infections is important. Streptococcus sanguinis, a Gram-positive bacterium, is one of the 
most abundant species in oral biofilm. It contributes to biofilm development in oral cavities and is 
one of the recognized causes of infective endocarditis. To study and identify biofilm genes in S. 
sanguinis, biofilm formation of 51 mutants was compared with the wild type SK36 strain using 
crystal violet (CV) staining in a microtiter plate. Confocal laser scanning microscopy (CLSM) and 
image analysis was done to compare biofilm formation by the mutant to the wild type SK36 strain. A 
biofilm mutant XG2_0351, encoding a type I signal peptidase (SPase I), was further investigated. 
SPase I cleaves proteins that are transported through secretory machinery and is necessary for the 
release of translocated preproteins from a cytoplasmic site of synthesis to 
extracytoplasmic/membrane destinations. S. sanguinis, like many Gram-positive bacteria, has 
multiple SPases I. The objective of this project is to investigate the distinctive role that SPase I plays 
in biofilm formation in S. sanguinis. Using a plate reader, the growth curves of the wild type strain 
SK36 and XG2_0351 were compared. The scanning electron microscope (SEM) was utilized to 
compare the cell surface morphologies. Coomassie staining was done to narrow the list of potential 
substrates of XG2_0351. CV staining and CLSM images indicated phenotypic differences between 
the SPase I mutant and SK36. The growth curves of XG2_0351 and SK36 showed no significant 
difference although SEM illustrated a difference in the cell surface morphologies. Coomassie 
staining illustrated a number of substrates that were present in SK36 but not XG2_0351. In addition 
bioinformatics was used to understand the gene function. In conclusion, XG2_0351 reduces biofilm 
formation in S. sanguinis but further research is necessary to elucidate the specific proteins that are 







role that SPase I plays in reduced biofilm formation in S. sanguinis will give a better 
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The highly developed oral microbiome is a diverse environment that is largely influenced by 
oral streptococci (Kreth, Merritt, & Qi, 2009). Streptococcus sanguinis, a gram-positive 
bacterium, is a known pioneer colonizer on freshly cleaned tooth surfaces and one of the 
abundant species in oral biofilm (Ge et al., 2008; Jenkinson & Lamont, 2005). As most members 
of the viridans group, S. sanguinis oxidizes hemoglobin in erythrocytes by secretion of H2O2 and 
produces alpha-hemolysis on blood agar (Barnard & Stinson, 1996; Xu et al., 2007). Through a 
variety of mechanisms, normal inhabitant streptococci form dental plaque which is involved in 
the development of caries. To initially colonize the tooth surface and form dental plaque, 
streptococci serve as a tether for the attachment of other microorganisms to a salivary 
glycoprotein-coated surface (Kolenbrander & London, 1993; Xu et al., 2007). One of these 
microorganisms is S. mutans, whose overgrowth is often associated with the development of 
dental caries (Kreth, Merritt, Shi, & Qi, 2005; Loesche, 1986). The shift from a healthy to 
cariogenic streptococcal environment is caused by coexistence and competition of interspecies 
interactions in a microbial community. Steering the outcome of interactions between species are 
determining environment conditions, such as nutritional availability, cell density, and pH (Kreth 
et al., 2005). Significantly higher number of S. sanguinis is reported in healthy subjects whereas 
there is almost no detectable level in those subjects with caries. An inverse relationship between 
commensal and pathogenic streptococci exists where a high levels S. sanguinis correlated with 
subsequent delayed acquisition of S. mutans (Caufield et al., 2000; Kreth et al., 2005). Through a 
well-regulated production of chemicals, such as H2O2 by S. sanguinis and mutacins by S. mutans 
these interspecies interactions are mediated (Kreth et al., 2005). Thus we can presume that the 







beneficial for oral health (Caufield et al., 2000; Xu et al., 2007). Although S. sanguinis is a 
member of the normal flora in the oral cavity and is considered benign, it has the potential to be 
pathogenic in patients through bacteremia (Ge et al., 2008; Turner, Das, Kanamoto, Munro, & 
Kitten, 2009; Xu et al., 2007). This opportunistic pathogen infection could lead to infective 
endocarditis or cause fatality in patients who are neutropenic (Bochud, Calandra, & Francioli, 





Biofilm is an accumulation of microorganisms embedded in a protective extracellular 
polymeric matrix that adheres to biotic or abiotic surfaces in nature (Hall, McGillicuddy, & 
Kaplan, 2014). This accumulation of either a single or multiple species lives in a nutrient-
sufficient ecosystem as a sessile microbial community. Biofilm exhibits a distinct 
physiologically altered pattern when compared to the gene expression and protein production of 
planktonic cells (Costerton, Stewart, & Greenberg, 1999; Donlan, 2002; Hall et al., 2014). 
Furthermore, an extracellular polymeric substance (EPS) matrix is produced to differentiate the 
biofilm-associated cells from the suspended planktonic cells (Donlan, 2000). The composition 
and structure of the polysaccharides in the EPS matrix determine their primary conformation. 
Usually the EPS in not uniform but varies spatially and temporally (Donlan & Costerton, 2002; 
Leriche, Sibille, & Carpentier, 2000). It is possible that the high level of hydration of the EPS 
prevents desiccation in some natural biofilms. The EPS can also impede the mass transport of 
antibiotics through the biofilm, which may promote their antimicrobial resistance properties 
(Donlan, 2000; Donlan, 2002). The formation of biofilm occurs in five major stages: initial 







Microbial surface components mediate attachment through surface proteins by recognizing 
adhesive matrix molecules (MSCRAMMs) (Foster, Geoghegan, Ganesh, & Hook, 2014; Lister 
& Horswill, 2014). Initially, bacteria adhered to the surface begin to multiply and differentiate, 
strengthening the attachment (Lister & Horswill, 2014). The maturation process occurs through 
the up-regulation of virulence factors, secretion of extra-cellular polymers, consumption of 
soluble nutrients, and recruitment of other bacterial species (Hall et al., 2014). When a biofilm is 
fully established it has a defined structure where the environment is conducive for the exchange 
of genetic material between cells (Donlan, 2002). Biofilm growth is an important advantage for 
bacteria because it provides a defense system against immune defenses such as macrophages. 
 
This can result in “frustrated phagocytosis” (Lister & Horswill, 2014; Scherr, Heim, Morrison, & 
Kielian, 2014). Biofilms demonstrate quorum sensing, which is cell-to-cell signaling that plays a 
role in cell attachment and detachment (Donlan, 2000). The cells of a biofilm may disperse by 
detachment caused by nutrient levels or quorum sensing, shearing of biofilm aggregates because 
of flow effects, or shedding of daughter cells from actively growing cells (Donlan, 2002). 
Eventually, individual cells from the original biofilm can disperse to start infection at new sights 
or mediate an acute infection (Costerton et al., 1999; Lister & Horswill, 2014). 
 
According to estimates by the U.S. Centers for Disease Control and Prevention and the 
National Institutes of Health, biofilm accounts for 65%-80% of microbial infections in human 
beings (Donlan, 2002; Hall et al., 2014). Infections that are biofilm-based have been discovered 
in almost all tissues of the human body (Hall et al., 2014). Many studies have shown that there is 
considerable evidence linking biofilm formation in the oral cavity to oral disease and 
consequently systemic infections. These systemic conditions include cardiovascular disease, 







(Hall et al., 2014; Seymour, Ford, Cullinan, Leishman, & Yamazaki, 2007). Biofilm growth has 
the ability to use a variety of defense mechanisms against infection so treatment and eradication 
of biofilm-associated infections are problematic and difficult (Hall et al., 2014). Cells in a 
biofilm show increased tolerance to antibiotics through different mechanisms. The biofilm 
matrix blocks access to actively growing cells by decreasing the antibiotic diffusion rates or 
physiologically dormant persister cells which are inherently resistant to antibiotics (de la Fuente-






Infective endocarditis (IE) is a potentially life-threatening microbial infection of the heart 
valves or endocardium (Cahill & Prendergast, 2015; Hoen & Duval, 2013; Selton-Suty et al., 
2012). This disease has an estimated annual incidence of 3 to 9 cases per 100,000 people in 
industrialized countries (Hoen & Duval, 2013; Selton-Suty et al., 2012). In 2016, there are many 
emerging treatments and therapies for endocarditis but the 1-year mortality rate remains at 30% 
(Cahill & Prendergast, 2015). If not treated, IE can result in severe complications such as 
congestive heart failure and can become fatal. 
 
Patients with prosthetic valves, intracardiac devices, unrepaired cyanotic congenital heart 
diseases, or a family history of IE have the highest rates of this illness. However, 50% of 
incidences of IE develop in patients with no known history of valve disease. There are several 
other risk factors for IE such as chronic rheumatic heart disease, hemodialysis, diabetes, HIV, 
and intravenous drug use (Hoen & Duval, 2013). In the United States, more than one third of the 







associated with age, the increased number of cases of IE among persons 65 years of age or older 
is clear (Hoen & Duval, 2013; Selton-Suty et al., 2012). 
 
Together, streptococci and staphylococci account for 80% of cases of IE. The proportions 
vary with regards to the source of infection, patient age, coexisting conditions, and valve (native 
vs. prosthetic) (Hoen & Duval, 2013). Recent studies have shown that staphylococci, specifically 
 
S. aureus, have surpassed streptococci as the most common cause of IE. IE by the streptococcal 
oral viridians group remain the most common in low-income countries (Cahill & Prendergast, 
2016; Yew & Murdoch, 2012). Although S. sanguinis has no direct role in oral disease, it is often 




Pathogenesis of Infective Endocarditis 
 
Conventional IE results when there is colonization of damaged valvular endothelium by 
circulating bacteria with specific adherence properties. Lesions that cause endothelial damage 
may be the result of turbulent blood, catheters, electrodes, or by repeated intravenous-drug use 
(Hoen & Duval, 2013). Certain types of congenital or acquired heart disease cause turbulent 
blood flow, traumatizing the endothelium and causing the deposition of fibrin and platelets on 
the damaged endocardium or endothelial surface. IE results when microbes invade the 
bloodstream and colonize this damaged site. Microbial organisms cause IE when they 
disseminate into the bloodstream and the intricately composed biofilm within the gingival tissue 
niche is disrupted. A disturbance of the delicate barrier between the oral biofilm and host tissues 
may cause periodontitis, gingivitis, pulpal or root canal infections. There is a heightened risk of 







procedures such as brushing, flossing, and chewing (Parahitiyawa, Jin, Leung, Yam, & 
Samaranayake, 2009). 
 
IE clinical manifestations can vary dramatically depending on the specific case. In 80% of 
cases fever is a prevalent symptom (Hoen & Duval, 2013; Selton-Suty et al., 2012). Also, a new 
murmur and worsening of a known murmur are reported. Less common signs are splenomegaly, 
splinter hemorrhages, Janeway’s lesions, Roth’s spots, conjunctival hemorrhage, sepsis, 
meningitis, unexplained heart failure, septic pulmonary emboli, stroke, acute peripheral arterial 
occlusion, and renal failure (Hoen & Duval, 2013; Richet et al., 2008). The most severe 
extracardiac problems of infective endocarditis are cerebral complications (Hoen & Duval, 2013; 
Sonneville et al., 2011; Thuny et al., 2007). 
 
Diagnostic methods for IE generally rely on clinical, microbiologic, and echocardiographic 
findings. To identify the causative microorganism, three sets of blood cultures are performed and 
the pathogen is identified in 90% of cases. Transthoracic echocardiography is performed to 
diagnose valvular lesions (Hoen & Duval, 2013). The polymerase chain reaction can be utilized 
to identify unculturable organisms in excised vegetations or systemic emboli (Beynon, Bahl, & 
Prendergast, 2006; Mylonakis & Calderwood, 2001). Appropriate treatment for patients with IE 
revolves around prolonged bactericidal antibiotic treatment to eradicate the causative pathogen 
and possible surgery to remove the infected material (Hoen & Duval, 2013). 
 
If there is no need for cardiac surgery, effective treatment for IE using antimicrobial agents 
begins in the hospital. Often this treatment is completed on an outpatient basis once the fever has 
resolved and follow-up blood cultures are negative. For common causes of IE, prolonged 
administration of a bactericidal antimicrobial agent or combination is currently recommended 







monotherapy to reduce the potential for resistance development and to provide a concerted 
antimicrobial effect (Cahill & Prendergast, 2016). There is a high frequency of adverse events in 
patients who are being treated for IE so therapy revision is important (Mylonakis & Calderwood, 
2001). The antimicrobial regimen can be modified depending on resistance patterns, severity of 
infection, presence or absence of prosthetic material, and culture results (Cahill & Prendergast, 
2016). The minimal inhibitory concentration (MIC) of penicillin is necessary to determine the 
optimal therapy for streptococcal infection. Antibiotic therapy for IE caused by some 
microorganisms is frequently unsuccessful, and surgery is generally recommended (Mylonakis & 
Calderwood, 2001). 
 
IE presents many challenges because it is heterogeneous and complex by nature. Even though 
there have been many advances in diagnostic procedures, antimicrobial treatments, and 
cardiovascular imaging it remains a serious threat to many lives (Cahill & Prendergast, 2015). As 
of 2015, IE has an incidence of 3 to 10 per 100,000 and has an in-hospitality of 20% (Cahill & 
Prendergast, 2015; Cahill & Prendergast, 2016). Therefore, it is imperative to study the causative 
agents and virulence factors of IE. 
 
 
Importance of Signal Peptidase I 
 
Almost one-third of all proteins need to be translocated through or into the cytoplasmic 
membrane because they function outside of the cytosol (Auclair, Bhanu, & Kendall, 2012). 
These preproteins are directed to the Sec- or Tat-translocation pathway by the signal sequence, 
an amino-terminal extension. In prokaryotes, signal peptidases (SPases) are classified into three 
groups: SPase I, II, and IV. SPase II and IV are necessary for cleaving signal peptides from 







are then transported in bacteria by the general secretion (Sec) pathway. However there is recent 
evidence that indicates that SPase I can also be transported by means of the twin arginine 
translocation (Tat) pathway (Auclair et al., 2012; Luke, Handford, Palmer, & Sargent, 2009). 
SPase I is essential to the cell for the release of translocated preproteins from the membrane 
when they are transported from a site of cytoplasmic synthesis to extracytoplasmic locations 
(Auclair et al., 2012; du Plessis, Nouwen, & Driessen, 2011). The protein extracytoplasmic 
location and specific secretion pathway destination are determined by the signal peptide which 
marks the protein with a zipcode. The signal peptidase enzyme has the responsibility of cleaving 
the signal peptide from the preprotein once the majority of it is translocated. This enzymatic 
action allows the protein to release from the membrane and correctly fold into a mature protein. 
SPase enzymes are critical for cell survival because without them, accumulation of preproteins at 
the membrane would occur and have a deleterious effect on the growth of the cell (Dalbey & 
Wickner, 1985; Auclair et al., 2012). Bacterial species such as E. coli have only one essential 
SPase I enzyme whiles others such as B. subtilis have multiple enzymes (Auclair et al., 2012; 
Meijer et al., 1995; Tjalsma et al., 1997; Tjalsma et al., 1998). S. sanguinis possesses two SPase I 
enzymes: XG2_0351 AND XG2_0849. The bacterial SPase I belongs to a unique group of serine 
endoproteases, which use a Ser-Lys catalytic dyad instead of the standard Ser-His-Asp triad 
utilized by eukaryotes. This distinctive feature makes SPase I a desirable antimicrobial target 

















Purpose of Study 
 
Identifying which genes in S. sanguinis can cause biofilm formation and their mechanisms is 
an important step in being able to effectively prevent and treat systemic infections that originate 
in the oral cavity. In this study we attempted to elucidate the role that SPases I plays in biofilm 
formation in S. sanguinis when a paralogue is available. In the future, S. sanguinis will be used 
as a model for further study of biofilm genes in other types of bacteria. 
 
Genome-wide deletion mutants of S. sangunis strain SK36 have been constructed in our 
laboratory. The comprehensive library of deletion mutants of SK36 provided the unique 
opportunity to apply a systems biology approach to investigate the effect of genetic mutations on 
biofilm formation. 
 
This study involved the observation of phenotypic characteristics of biofilm formation by the 
non-essential deletion mutants and the wild type of S. sanguinis SK36 using crystal violet 
staining and confocal laser scanning microscopy. Cell morphologies for selected mutant 
XG2_0351 and SK36 were compared through visualization by scanning electron microscopy. To 
compare the growth between SK36 and XG2_0351 the growth curves were examined using a 
plate reader. Computational prediction data was used to gain more knowledge about gene 
interactions and functional similarities to other species. Finally, coomassie staining was done to 



















METHODS AND MATERIALS 
 
Bacterial strain and mutants 
 
S. sanguinis strain SK36 that was used in this study (Table 1) was isolated from human 
dental plaque (Kilian, Mikkelsen, & Henrichsen, 1989). Single gene deletion mutants for the 
SK36 strain were previously constructed using a recombinant PCR method (Figure 1). Utilizing 
the complete S. sanguinis SK36 genome sequence, three sets of primers (F1/R1, F2/R2, and 
F3/R3) were designed. Primers were constructed to amplify a linear DNA fragment containing a 
kanamycin resistance cassette flanked by upstream and downstream sequences of the targeted 
gene. The 5’ ends of the F2 and R2 of primers of the kanamycin cassette were created to 
complement the sequences of DNA that flank the target gene (Xu et al., 2011). The linear 
recombinant PCR amplicons containing the kanamycin cassette (Turner, Das, Kanamoto, Munro, 
& Kitten, 2009) flanked by S. sanguinis DNA were transformed into competent S. sanguinis 
cells and integrated into the S. sanguinis genome via double crossover recombination (Ge et al., 
2008). A genome-wide mutant library containing 2,048 deletion mutants was constructed using a 
96 well high-throughput format (Chen et al., 2011; Xu et al., 2007). To determine putative gene 
functions proteins were searched against the previously annotated genome (Ge et al., 2008; Xu et 
al., 2007). Genes of SK36 are referred to as “SSA” followed by the corresponding gene number 























































































Table 1.   
Strain Phenotype Source 
S. sanguinis   
SK36 Human dental plaque isolate [Kilian 1989, Xu 2007] 
SK36 mutants All non-essential gene deletion mutants [Xu 2007, Chen 2011] 


















































Figure 1. Schematic representation of the insertion of kanamycin (Km) resistance gene cassette 




































































































































Crystal Violet Assay 
 
To study and identify biofilm genes in S. sanguinis, 51 mutants were compared with the wild 
type SK36 strain using the microtiter dish biofilm formation assay. Using preliminary data from 
our lab (Table 2), the set of 51 mutants were tested for biofilm formation using the O’Toole 
method to observe bacterial adherence to an abiotic surface (O'Toole, 2011). This method was 
also used to test the downstream gene of XG2_0351, as well as its paralogue: XG2_0849. SK36 
and mutants were grown anaerobically in BHI and BHI supplemented with kanamycin 
respectively, and incubated at 37°C for 16 hours. A multichannel pipette was used to inoculate a 
96-well plate with 99 µl of biofilm medium supplemented with 1% sucrose and 1 µl of overnight 
culture of SK36 of each mutant for 8 repeats. One column of 8 wells was loaded with medium 
alone as a negative control. The total bacterial growth was determined by measuring the 
absorbance at 450 nm with a Synergy H1 Hybrid Reactor (BioTek, VT, USA) microplate reader. 
We decanted the media and then removed the remaining planktonic cells by gently rinsing with 
200 µl of distilled H2O. 50 µl of 0.4% (wt/vol) crystal violet (CV) solution was added to each 
well and was left for 15 minutes to dry. Wells were rinsed three times with 200 µl of distilled 
H2O and air-dried. The CV was solubilized by 200 µl of 33% acetic acid. After 30 minutes, 100 
µl from each well was transferred to a new plate and the absorbance at 600 nm was measured by 
a Synergy H1 Hybrid Reactor (BioTek, VT, USA) microplate reader. The results from microtiter 
staining were statistically analyzed by ANOVA. The significance was set as P-value <0.05 (Ge 














Confocal Laser Scanning Microscopy (CLSM) and Image Analysis 
 
Confocal laser scanning microscopy and image analysis was used to further study and identify 
biofilm genes in S. sanguinis. Six wells in a 12 well-plate were filled with 1000 µl of biofilm 
medium supplemented with 1% sucrose and inoculated with 10 µl of overnight culture. The first 
column contained SK36 and the second contained a mutant for 3 repeats each. Overnight 
biofilms were rinsed 1 time with 1000 µl of PBS to remove the unattached bacteria. For 15 
minutes, biofilms were labeled using live staining. This was done with 1.5 µM SYTO9 (a green 
fluorescent dye that can cross intact membranes). Afterwards the wells were rinsed with 1000 µl 
of PBS to remove the remaining dye. The biofilms were viewed through a 10x dry lens with a 
Zeiss LSM 710 confocal laser scanning microscope. Green fluorescence was imaged and an 
image stack of 1 randomly chosen spot was collected for each sample. The computer program 
ImageJ analyzed CLSM images. Image stacks were converted to individual Tiff images for the 
front, middle, and side of each sample. The image stacks of biofilm grown by the mutant were 
compared to growth by the wild type by using the T-test. This method was also used to test the 
downstream gene of XG2_0351, as well as its paralogue: XG2_0849. 
 
Confocal Laser Scanning Microscopy and Scanning Electronic Microscopy were performed 
at the VCU Department of Anatomy and Neurobiology Microscopy Facility, supported in part, 




















Examination of Mutant Growth in vitro 
 
This experiment was done to elucidate and compare growth rates of SK36 and XG2_0351. 
The wild type and mutant were inoculated individually and then measured for three trials 




Elucidated Gene Functions using Clusters of Orthologous Groups 
 
Using PubMed (http://www.ncbi.nlm.nih.gov/pubmed), we searched for mutant genes that 
are organized into operons (Table 3). Uniprot (http://www.uniprot.org/) was utilized to search 
clusters of orthologous groups (COGs) (Table 3). 
 
 
STRING Analysis and Gene Co-occurrence Network 
 
The STRING database (http://string-db.org/) provided a way to visualize and predict protein-
protein interactions of XG2_0351 through bioinformatics data (Figure 7A). The co-occurrence 
network shows the relationship between XG2_0351 with other bacterial species (Figure 7B). 
 
 
Scanning Electron Microscopy (SEM) Analysis of S. sanguinis WT and Mutant Cells 
 
The cell morphologies of S. sanguinis SK36 and selected mutant XG2_0351 were examined 
using SEM (Figure 5). The two samples were deposited onto a 0.1 μm disposable Millipore filter 
to remove medium. Samples were fixed using 2% glutaraldehyde in 0.1 M sodium cacodylate 
buffer (pH 7.4) for 30 min, followed by 1% osmium tetroxide in 0.1 M sodium cacodylate buffer 
(pH 7.4). The samples embedded in the filters were then dehydrated in ethanol followed by 







onto stubs and coated with gold for three minutes (EMS– 550 Automated Sputter Coater, 
Electron Microscopy Sciences, Hatfield, PA). Micrographs were taken at 15,000× total 






This staining assay was done to elucidate which proteins XG2_0351 is targeting (Figure 11). 
We inoculated the stocked strain into 5 ml medium (e.g. BHI) in a 15 ml round-bottom tube. 
After this we prepared 3 round-bottom tubes of 15 ml containing 5 ml medium, and then 
incubated them in an anaerobic jar at 37 °C for overnight. Then we transferred 50 μl overnight 
bacterial culture into each of 3 pre-incubated conical tubes and incubated at the same condition 
as previously stated to mid log-phase (about 4 hours). All of the following steps were done at 4 
°C. Bacterial cells were centrifuged for 10 min at 4,000 rpm using Sorvall Legend RT centrifuge 
(MN, USA). Following this we added 10 μl protease inhibitor cocktail (Sigma P8430) and 
DNase (1 μg/ml) to 1 ml non-denaturing lysis buffer (PBS, EDTA=5 mM, pH = 7.4) to 10
6
 cells 
in mid log-phase bacterial culture. We re-suspended the pellets by pipetting up and down several 
times. The suspension was transferred into the 2 ml Lysing Matrix B Beads. Cells were disrupted 
in the Fast Prep 24 for 30s at level 4. Then we sonicated for short pulses (5-10 sec) with pauses 
(10-30 sec) to re-establish a low temperature. We centrifuged for 10s at maximum speed and 
transferred supernatant into a new tube. Then we determined the volume of the supernatant and 
quantitated the protein in sample using Pierce BCA Protein Assay kit (Cat #23227, IL, USA). 15 









Brilliant Blue R-250 solution (Bio-Rad, USA) for 4 hours. Finally, we washed with washing 


































































We compared 51 mutants to SK36 using crystal violet staining to determine if there is a 
statistically significant difference in biofilm formation (Figure 2). Using the ANOVA statistical 
test, we determined t-test with p-values <0.05 were statistically different. We found that 41 
mutants formed biofilms that were statistically significant when compared to SK36. Using a 
multiple comparison method known as Dunnett's test, we found that XG2_0351 has a p value 
<.0001 when compared to SK36. 25 mutants that showed less biofilm formation than SK36 were 
viewed via CLSM. Using CLSM, z-stacks were created by stacking successive slices, which 
were then processed into a 3D image using ImageJ software (Figure 3). The z-stack for 
XG2_0351 showed effectively no biofilm formation and therefore, was much thinner than SK36. 
The downstream mutant, XG2_0350 was tested to rule out the possibility of the polar effect 
(Figure 8). XG2_0351 was selected for further investigation based on phenotypic differences 
with SK36 that were determined by CV staining and CLSM. 
 
SEM was used to visualize the morphological differences between SK36 and type I 
signal peptidase mutant XG2_0351 (Figure 5). Biofilm did not form during CV staining or 
CLSM, XG2_0351 showed growth in SEM images. Although, the mutant chains were much 
shorter in length and had a different shape than SK36. To gain more insight into the growth 
differences we looked at the growth curves by using a plate reader (Figure 6). Three separate 
repetitive trials showed that the growth rate of SK36 and XG2_0351 are not significantly 
different. 
 
Through computational prediction methods, the STRING database predicted that this 
signal peptidase I protein interacts with signal recognition particles and several ribosomal 







Firmicutes phylum (Figure 7B). CLSM was utilized to visualize XG2_0849, the paralogue of 
XG2_0351, for biofilm formation (Figure 9). The mutant showed a slight difference in biofilm 
formation when compared to SK36 but lacked the dramatically decreased effect seen by 
XG2_0351. Finally, the coomassie assay was done to see the concentrations of proteins that are 
in SK36 but missing in XG2_0351 (Figure 11). Nine substrates of SPase I mutant, XG2_0351, 
that were previously shown through CV staining and confocal imaging to exhibit reduced 
























































































































Biofilm Mutant Gene Annotation 
  
XG2_0004 Lipoprotein, putative 
  
XG2_0036 Secreted protein, possible function in cell-wall metabolism (amidase), putative (N- 
 acetylmuramoyl-L-alanine amidase) 
XG2_0048 Transcriptional regulator, TetR/AcrR family, putative 
  
XG2_0115 50S ribosomal protein L29, putative 
  
XG2_0144 Transcriptional regulator, TetR family, putative 
  
XG2_0299 Integral membrane protein / nodulin 21-like protein 
  
XG2_0305 Heat-inducible transcription repressor/Conserved hypothetical protein/p-hydroxybenzoic acid 
 efflux subunit AaeB 
XG2_0351 Signal peptidase I, putative 
  
XG2_0363 D-alanine/glycine/Na permease, putative 
  
XG2_0364 Serine/threonine:Na+ symporter, putative 
  
XG2_0387 Transcriptional regulator, GntR family, putative 
  
XG2_0460 Multiple antibiotic resistance operon transcription repressor (MarR), putative 
  
XG2_0613 Glucosyltransferase, putative 
  
XG2_0708 Hypothetical protein ( isoprenylcysteine carboxyl methyltransferase (ICMT) family protein) 
  
XG2_0758 Ornithine acetyltransferase / amino-acid acetyltransferase, putative 
  
XG2_0767 Diacylglycerol kinase catalytic domain protein, putative 
  
XG2_0805 Collagen-binding surface protein, putative 
  
XG2_0816 Copper transport operon or penicillinase transcription repressor, putative 
  
XG2_0879 Cell division regulator, negative regulator of FtsZ septation ring formation, putative 
  
XG2_0960 Sensor protein ciaH, putative 
  
XG2_1030 Transcriptional regulator, TetR family, putative 
  
XG2_1064 Hypothetical protein (dextransucrase/glucansucrase, N-acetylmuramoyl-L-alanine amidase, 
 family 2 ) 
XG2_1068 Transcriptional regulator, LysR family (capsular polysaccharide biosynthesis regulation), 
 putative 
XG2_1103 Hypothetical protein/ABC transporter?/capsular polysaccharide biosynthesis 
 protein?/PAS/PAC sensor signal transduction histidine kinase 
XG2_1171 Tyrosine recombinase xerC 
  
XG2_1219 Sortase, putative 
  
XG2_1271 DHH subfamily 1 protein/Exopolyphosphatase-related proteins 
  
XG2_1301 Conserved uncharacterized protein, possible surface protein 
  
XG2_1309 Predicted RNA-binding protein (contains KH domain), very conserved, putative 
  
XG2_1363 FmtA-like protein, putative 
  
XG2_1368 Hypothetical protein (beta-lactamase) 
  





XG2_1451 Exonuclease RexA, putative 
  
XG2_1476 Phosphoglycerol transferase and related proteins, alkaline phosphatase superfamily, putative 
  
XG2_1741 ABC-type Fe3+-siderophores transporter, ATPase component, putative 
  
XG2_1744 Iron compound ABC transporter, permease protein, putative 
  
XG2_1792 Preprotein translocase subunit YidC, putative 
  
XG2_1845 Serine/threonine protein kinase, putative 
  
XG2_1984 Cell surface SD repeat antigen precursor, putative 
  
XG2_2094 Spermidine synthase/hemolysin-type calcium-binding region 
  
XG2_2128 Transporter, major facilitator family protein/ transport of a lantibiotic 
  
XG2_2138 RNA-binding protein, Jag family, putative 
  
XG2_2150 Transglycosylase associated protein/Predicted membrane protein, putative 
  
XG2_2170 Peptidase, S54 (membrane-associated serine protease) 
  
XG2_2205 Transcription antitermination factor NusG, putative 
  
XG2_2234 Phosphatidylserine/phosphatidylglycerophosphate/cardiolipin synthases and related enzymes, 
 phospholipase D family, putative 
XG2_2320 Uncharacterized protein 
  
XG2_2331 Protein involved in D-alanine esterification of lipoteichoic acid and wall teichoic acid (D- 
 alanine transfer protein), putative 
XG2_2333 Integral membrane protein, putative 
  
XG2_2335 D-Ala-teichoic acid biosynthesis protein, putative 
  
XG2_2346 3-oxoacyl-[acyl-carrier-protein] synthase III, putative 
  
XG2_2364 Immunodominant staphylococcal antigen A precursor, putative 
  







































































































SSA COG Function Operon/Synteny Paralogues 
 Predicted small periplasmic lipoprotein YifL (function   
SSA_0004 Unknown SSA_0004  
SSA_0036 Surface antigen SSA_0036  
SSA_0048 DNA-binding transcriptional regulator, AcrR family SSA_0048-0047  
SSA_0115 Ribosomal protein L29 SSA_0143-0104  
SSA_0144 DNA-binding transcriptional regulator, AcrR family SSA_0144-0145  
SSA_0299 Predicted Fe2+/Mn2+ transporter, VIT1/CCC1 family SSA_0311-0297  
 Uncharacterized membrane protein YgaE, UPF0421/DUF939   
SSA_0305 Family SSA_0311-0297  
SSA_0351 Signal peptidase I SSA_0350-0352  
SSA_0363 Na+/alanine symporter SSA_0363-0359  
SSA_0364 Na+/serine symporter SSA_0364  
SSA_0387 DNA-binding transcriptional regulator, GntR family SSA_0387-0385  
SSA_0460 DNA-binding transcriptional regulator, MarR family SSA_0505-0456  
SSA_0613 Glucan-binding domain (YG repeat) SSA_0613-0610  
 Uncharacterized protein YpbQ, isoprenylcysteine carboxyl   
SSA_0708 Methy SSA_0706-0708  
SSA_0758 N/A SSA_0767-0746  
SSA_0767 Diacylglycerol kinase family enzyme SSA_0767-0746  
SSA_0805 Uncharacterized surface anchored protein SSA_0802-0812  
SSA_0816 Predicted transcriptional regulator SSA_0815-0820  
SSA_0879 Septation ring formation regulator EzrA SSA_0873-0783  
SSA_0960 Signal transduction histidine kinase SSA_0923-0963  
SSA_1030 DNA-binding transcriptional regulator, AcrR family SSA_1030  
SSA_1064 N/A SSA_1064  
SSA_1068 DNA-binding transcriptional regulator, LysR family SSA_1065-1122  
SSA_1103 N/A SSA_1065-1122  
SSA_1171 Integrase SSA_1171  
SSA_1219 Sortase (surface protein transpeptidase) SSA_1218-1220  
 nanoRNase/pAp phosphatase, hydrolyzes c-di-AMP and   
SSA_1271 oligoRNAs SSA_1271-1272  
SSA_1301 N/A SSA_1301-1318  
 Predicted RNA-binding protein YlqC, contains KH domain,   
SSA_1309 UPF010 SSA_1301-1318  
   1363 vs 1368= 
   20% coverage, E- 
   53,ID 77%; 1363 
   vs 1371= 100% 
SSA_1363 CubicO group peptidase, beta-lactamase class C family SSA_1363-1366 cov, E 0, ID 58% 
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   1368 vs 1363: 
   cov= 99%, e 52, 
SSA_1368 CubicO group peptidase, beta-lactamase class C family SSA_1368-1372 77% ID 
   1371 vs 
   1363=100% cov, E 
SSA_1371 CubicO group peptidase, beta-lactamase class C family SSA_1368-1372 0, ID 58% 
 ATP-dependent exoDNAse (exonuclease V) beta subunit   
SSA_1451 (contains SSA_1402-1475  
 Phosphoglycerol transferase MdoB or a related enzyme of   
SSA_1476 AlkP s SSA_1476-1479  
 ABC-type cobalamin/Fe3+-siderophores transport system,   
SSA_1741 ATPase SSA_1741-1744  
 ABC-type Fe3+-siderophore transport system, permease   
SSA_1744 Component SSA_1744-1741  
 Membrane protein insertase Oxa1/YidC/SpoIIIJ, required for   
SSA_1792 The SSA_1792-1791  
SSA_1845 Serine/threonine protein kinase SSA_1840-1852  
SSA_1984 N/A SSA_1972-2019  
SSA_2094 N/A SSA_2082-2121  
SSA_2128 MFS family permease SSA_2122-2129  
 Predicted RNA-binding protein Jag, conains KH and R3H   
SSA_2138 Domains SSA_2136-2150  
 Uncharacterized membrane protein YeaQ/YmgE,   
SSA_2150 transglycosylase-a SSA_2150-2136  
SSA_2170 Membrane associated serine protease, rhomboid family SSA_2170-2185  
SSA_2205 Transcription antitermination factor NusG SSA_2205  
 Phosphatidylserine/phosphatidylglycerophosphate/cardiolipin   
SSA_2234 Sy SSA_2211-2246  
SSA_2320 N/A SSA_2321-2296  
SSA_2331 Poly D-alanine transfer protein DltD, involved inesterificatio SSA_2330-2335 Not a paralog 
 D-alanyl-lipoteichoic acid acyltransferase DltB, MBOAT   
SSA_2333 Superfamily SSA_2330-2335 Not a paralog 
SSA_2335 N/A SSA_2330-2335 Not a paralog 
SSA_2346 3-oxoacyl-[acyl-carrier-protein] synthase III SSA_2346-2360  
SSA_2364 N/A SSA_2364-2371  



























































































Paralogue   
(Da)      
      
 SSA_0012 Beta-lactamase class A, putative 48396.6418 No 
      
 
SSA_0015 
Membrane ATPase FtsH, degrades sigma32 (integral 
72536.7981 No   membrane cell-division Zn metallo-peptidase), putative      
      
 SSA_0017 Cell shape determining protein MreC, putative 29544.234 No 
      
 
SSA_0019 
Secreted antigen GbpB/SagA; peptidoglycan hydrolase; 
42469.4498 Yes   PcsB protein precursor, putative      
      
 SSA_0021 Hypothetical protein 19560.3138 No 
      
 
SSA_0036 
Secreted protein, possible function in cell-wall metabolism 
72153.7086 Yes   (amidase), putative      
      
 SSA_0094 Cell wall metabolism, LysM type protein, putative 38190.3647 Yes 
      
 SSA_0140 Copper-translocating P-type ATPase, putative 79654.5004 Yes 
      
 SSA_0146 DNA repair ATPase, putative 84740.3229 Yes 
      
 SSA_0157 Hypothetical protein 9830.5367 No 
      
 SSA_0165 Conserved hypothetical protein 22562.2951 No 
      
 SSA_0167 Hypothetical protein (Asparagine/proline-rich) 33290.0671 No 
      
 SSA_0173 23S rRNA m1G745 methyltransferase, putative 32071.4906 No 
      
 SSA_0175 Penicillin-binding protein 1B, putative 80849.4257 Yes 
      
 
SSA_0181 
Glycosyltransferase (vectorial glycosyl polymerization 
49942.7224 No   (VGP) family), putative      
      
 SSA_0186 Competence protein ComYC, putative 11434.1479 No 
      
 SSA_0187 Competence protein ComYD, putative 15922.1403 No 
      
 SSA_0210 Conserved hypothetical protein 10675.0381 No 
      
 SSA_0215 Periplasmic sugar-binding protein (ribose porter), putative 36734.0881 Yes 
      
 SSA_0218 Sugar-binding periplasmic protein, putative 48332.3799 Yes 
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SSA_0227 Collagen-binding surface protein, putative 66956.5729 Yes 
    
SSA_0243 Cyclo-nucleotide phosphodiesterase, putative 86679.2483 Yes 
    
SSA_0257 N-acetylmuramidase/lysin, putative 104901.3981 Yes 
    
SSA_0273 Hypothetical protein 50478.7114 No 
    
SSA_0291 Oxidoreductase, putative 29913.2519 Yes 
    
SSA_0301 Conserved hypothetical protein 21121.8259 Yes 
    
SSA_0303 Surface protein C 162864.2939 Yes 
    
SSA_0304 
Bacterial cell wall degradation (CHAP/LysM domains), 
23670.7359 Yes 
putative    
    
SSA_0396 Conserved hypothetical protein 35467.6105 No 
    
SSA_0398 Conserved hypothetical protein, beta-lactamase family 67219.477 Yes 
    
SSA_0400 Conserved hypothetical protein, beta-lactamase family 67173.1453 Yes 
    
SSA_0424 Exopolysaccharide biosynthesis protein, putative 32497.4588 No 
    
SSA_0453 
Type II secretory pathway, pullulanase PulA glycosidase, 
136563.4945 Yes 
putative    
    
SSA_0477 
Cobalamin biosynthesis protein CbiM (ABC-type cobalt 
27984.33 No 
transporter), putative    
    
SSA_0478 Cobalt transport protein cbiN, putative 11108.6369 No 
    
SSA_0498 
ABC-type dipeptide/oligopeptide/nickel transport systems, 
29272.4342 Yes 
permease components, putative    
    
SSA_0500 Peptide ABC transporter, permease protein, putative 35018.2904 Yes 
    
SSA_0521 Ethanolamine utilization protein EutL, putative 22395.7496 Yes 
    
SSA_0565 Conserved hypothetical protein 92304.059 No 
    
SSA_0607 ABC transporter, permease component, putative 87572.3394 No 
    
SSA_0610 LemA-like protein, putative 20939.6228 No 
    
SSA_0613 Glucosyltransferase, putative 175399.2 Yes 
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SSA_0684 Fibril-like structure subunit FibA, putative 139324.4303 Yes 
    
SSA_0689 Penicillin-binding protein 2B, putative 75285.4986 Yes 
    
SSA_0723 Hypothetical protein 5304.2581 No 
    
SSA_0726 FmtA-like protein, putative 67437.3138 Yes 
    
SSA_0747 DD-carboxypeptidase, putative 50393.737 Yes 
    
SSA_0793 DNA-entry nuclease, putative 31237.3587 No 
    
SSA_0801 Mur ligase family protein, putative 49483.2476 No 
    
SSA_0803 Conserved hypothetical protein 27132.1818 No 
    
SSA_0805 Collagen-binding surface protein, putative 60556.5712 Yes 
    
SSA_0871 Cell division protein FtsX, putative 34500.8682 No 
    
SSA_0881 Lipoprotein, putative 25788.1976 Yes 
    
SSA_0897 Two component system histidine kinase, putative 52198.3589 Yes 
    
SSA_0904 CshA-like fibrillar surface protein A 316344.8238 Yes 
    
SSA_0905 CshA-like fibrillar surface protein B 207893.0251 Yes 
    
SSA_0906 CshA-like fibrillar surface protein C 283050.8434 Yes 
    
SSA_0908 
ABC-type uncharacterized transport system, periplasmic 
35242.882 No 
component, putative    
    
SSA_0947 Hypothetical protein 22254.0843 Yes 
    
SSA_0956 Surface protein D 153644.0111 Yes 
    
SSA_0963 
Peptidoglycan N-acetylglucosamine deacetylase A, 
52559.0496 No 
putative    
SSA_0967 Conserved hypothetical protein 24999.4402 No 
    
SSA_0970 Conserved hypothetical protein 17131.3139 Yes 
    
SSA_0991 Deoxyribonuclease, putative 28746.0106 No 
    
SSA_1018 Zinc metalloprotease zmpC precursor, putative 339189.1463 Yes 
    
SSA_1019 Collagen-binding surface protein, putative 87795.544 Yes 
    
SSA_1023 Von Willebrand factor-binding protein precursor, putative 100844.6464 No 
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SSA_1042 Xylanase/chitin deacetylase, putative 35656.9693 No 
    
SSA_1051 
Spermidine/putrescine ABC transporter, 
40929.175 No 
spermidine/putrescine-binding protein, putative    
    
SSA_1052 Hypothetical protein 14191.2411 No 
    
SSA_1063 Peptidoglycan-binding domain-containing protein, putative 48445.9462 No 
    
SSA_1064 
Conserved hypothetical protein (contains glucan-binding 
28533.3142 Yes 
domain)    
    
SSA_1065 Beta-hexosamidase A, putative 99533.6984 No 
    
SSA_1095 Peptidoglycan hydrolase, putative 25795.2184 No 
    
SSA_1106 IgA-specific metalloendopeptidase 208437.007 Yes 
    
SSA_1112 Cell wall surface anchor family protein, putative 56954.5939 No 
    
SSA_1118 Peptide methionine sulfoxide reductase, putative 41843.5912 Yes 
    
SSA_1130 Iron-dependent peroxidase, putative 45410.802 No 
    
SSA_1132 TatC, sec-independent protein translocase, putative 28740.0497 No 
    
SSA_1148 Beta-glucosides PTS, EIIC, putative 47963.4949 Yes 
    
SSA_1158 Conserved hypothetical protein 31692.5521 Yes 
    
SSA_1161 Conserved hypothetical protein, possibly secreted 35214.2297 No 
    
SSA_1219 Sortase, putative 27918.7002 Yes 
    
SSA_1221 L-lactate dehydrogenase, putative 35328.6664 No 
    
SSA_1234 5'-nucleotidase, putative 76340.7606 Yes 
    
SSA_1274 Hypothetical protein 74589.9418 No 
    
SSA_1301 Conserved uncharacterized protein, possible surface protein 90577.9472 Yes 
    
SSA_1339 Pneumococcal histidine triad protein D precursor, putative 131547.081 Yes 
    
SSA_1359 
Arginine/histidine ABC transporter, permease component, 
78675.5391 Yes 
putative    
    
SSA_1363 FmtA-like protein, putative 66457.5498 Yes 
    
SSA_1365 FmtA-like protein, putative 35566.1972 Yes 
    
SSA_1368 Hypothetical protein 12234.0033 Yes 
    
SSA_1369 FmtA-like protein, putative 67107.2338 Yes 
    
SSA_1371 FmtA-like protein, putative 66339.2022 Yes 
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SSA_1372 Hypothetical protein 6968.0981 No 
    
SSA_1390 Hypothetical protein 18387.7033 No 
    
SSA_1391 Hypothetical protein 24811.6397 No 
    
SSA_1408 Conserved hypothetical protein 21550.7326 No 
    
SSA_1415 Oxidoreductase, putative 39914.9737 No 
    
SSA_1434 Conserved uncharacterized Firmicutes protein 5894.894 No 
    
SSA_1481 FmtA-like protein, putative 67460.5781 Yes 
    
SSA_1489 Hypothetical protein 39767.8167 Yes 
    
SSA_1525 Lyzozyme M1 (1,4-beta-N-acetylmuramidase), putative 32425.9415 No 
    
SSA_1532 
Membrane-fusion protein / periplasmic component of 
40852.7964 Yes 
efflux system, putative    
    
SSA_1544 Conserved uncharacterized protein 17995.4248 No 
    
SSA_1567 
Polar amino acid ABC transporter, amino acid-binding 
29898.7625 Yes 
protein, putative    
    
SSA_1588 
Conserved ABC-type antimicrobial permease-like protein, 
101024.5143 No 
putative    
    
SSA_1591 Dipeptidase, putative 75007.1993 Yes 
    
SSA_1593 Dipeptidase, putative 61779.1816 Yes 
    
SSA_1594 Metalloendopeptidase, putative 79277.3956 Yes 
    
SSA_1596 Hypothetical protein 36580.2214 Yes 
    
SSA_1597 Hypothetical protein 37837.2035 Yes 
    
SSA_1598 Hypothetical protein 36877.3853 Yes 
    
SSA_1599 Hypothetical protein 38230.0062 Yes 
    
SSA_1626 DNA translocase ftsK, putative 84255.6297 Yes 
    
SSA_1631 Sortase-like protein, putative 33177.1937 Yes 
    
SSA_1632 Surface protein, putative 51822.5553 Yes 
    
SSA_1633 FimA fimbrial subunit-like protein, putative 51569.2038 Yes 
    
SSA_1634 Heme utilization/adhesion exoprotein, putative 53218.4441 Yes 
    
SSA_1635 Hypothetical protein 77849.1805 Yes 
    
SSA_1649 Conserved hypothetical transmembrane protein 37430.4913 Yes 
    
SSA_1650 3-Ketoacyl-ACP reductase, putative 25126.5123 Yes 
    
SSA_1653 Hypothetical protein 37671.6974 Yes 
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SSA_1663 Collagen-binding protein A 163017.8908 Yes 
    
SSA_1671 Conserved hypothetical protein 35911.9174 No 
    
SSA_1673 Hypothetical protein 6245.3806 No 
    
SSA_1680 
ABC-type bacitracin resistance protein A, permease 
74398.8545 Yes 
component, putative    
    
SSA_1692 Phospho-B-galactosidase LacG, putative 54094.9495 Yes 
    
SSA_1744 
Iron compound ABC transporter, permease protein, 
36333.7876 Yes 
putative    
SSA_1750 Extracellular nuclease, putative 80467.6835 No 
    
SSA_1793 Histidine kinase (sensor protein), putative 47218.5222 Yes 
    
SSA_1871 Penicillin-binding protein 2X, putative 84338.3141 Yes 
    
SSA_1882 Subtilisin-like serine proteases, putative 162877.6003 Yes 
    
SSA_1909 Transcriptional attenuator LytR, putative 44849.8077 Yes 
    
SSA_1951 Penicillin-binding protein 3, putative 45867.2977 Yes 
    
SSA_1960 Conserved hypothetical protein 70290.9424 No 
    
SSA_1961 
Amino acid ABC transporter, amino acid-binding 
57437.3438 Yes 
protein/permease protein, putative    
    
SSA_1984 Cell surface SD repeat antigen precursor, putative 99884.0631 Yes 
    
SSA_1985 Conserved hypothetical protein 72476.2762 Yes 
    
SSA_1991 Pneumococcal histidine triad protein A, putative 90478.1281 Yes 
    
SSA_2004 Zinc metalloprotease zmpB precursor, putative 209552.9886 Yes 
    
SSA_2014 D-alanyl-D-alanine carboxypeptidase, putative 28870.2489 Yes 
    
SSA_2020 Conserved hypothetical protein 114163.2144 No 
    
SSA_2023 Fructan beta-fructosidase precursor, putative 155910.6148 Yes 
    
SSA_2056 Cinnamoyl ester hydrolase, putative 34354.6188 Yes 
    
SSA_2060 Arabinose efflux permease, putative 42316.0242 No 
    
SSA_2074 Preprotein translocase subunit YajC, putative 12123.8761 No 
    




Amino acid ABC transporter, periplasmic amino acid- 
32773.4118 Yes 
binding protein, putative    
    
SSA_2103 Hypothetical protein 7403.5321 No 
    
SSA_2121 Cell wall surface anchor family protein, putative 171211.2214 Yes 
    
SSA_2169 Glucose-1-phosphate uridylyltransferase, putative 35605.5304 Yes 
    
SSA_2248 Conserved hypothetical protein 18481.9426 No 
    
SSA_2250 
ABC-type antimicrobial peptide transporter, permease 
74446.4569 No 
component, putative    
    
SSA_2264 Conserved hypothetical protein 18976.0874 No 
    
SSA_2269 Conserved hypothetical protein 34777.2793 Yes 
    
SSA_2281 Conserved hypothetical protein 17118.3266 No 
    
SSA_2282 Phage infection protein, putative 107220.5308 Yes 
    
SSA_2301 
S-layer protein/ peptidoglycan endo-beta-N- 
21506.3392 No 
acetylglucosaminidase, putative    
    
SSA_2307 Hypothetical protein 56585.6564 No 
    
SSA_2313 Hypothetical protein 16101.3788 Yes 
    
SSA_2320 Hypothetical protein 125568.1653 No 
    
SSA_2321 Cation (Co/Zn/Cd) efflux protein, putative 32405.2702 Yes 
    
SSA_2338 Conserved uncharacterized protein 35945.4865 Yes 
    
SSA_2340 Conserved hypothetical protein 43813.4783 No 
    
SSA_2364 
Immunodominant staphylococcal antigen A precursor, 
19901.7084 No 
putative    
    
SSA_2381 DegP protein, putative 40827.0835 No 





























































































    
 Gene ID Gene Annotation 
    
  
XG2_0036 
Secreted protein, possible function in cell-wall metabolism 
  
(amidase), putative (N-acetylmuramoyl-L-alanine amidase)    
 XG2_0613 Glucosyltransferase, putative 
    
 XG2_0805 Collagen-binding surface protein, putative 
    
  
XG2_1064 
Hypothetical protein (dextransucrase/glucansucrase,  N- 
  
acetylmuramoyl-L-alanine amidase, family 2 )    
 XG2_1219 Sortase, putative 
    
 XG2_1301 Conserved uncharacterized protein, possible surface protein 
    
 XG2_1363 FmtA-like protein, putative 
    
 XG2_1368 Hypothetical protein (beta-lactamase) 
    
 XG2_1371 FmtA-like protein, putative (beta-lactamase family protein) 
    
 XG2_1744 Iron compound ABC transporter, permease protein, putative 
    
 XG2_1984 Cell surface SD repeat antigen precursor, putative 
    
 XG2_2320 Uncharacterized protein 
    
 XG2_2364 Immunodominant staphylococcal antigen A precursor, putative 










































Figure 2. Crystal violet assay of 51 biofilm mutants. Yellow star signifies selected mutant, 
XG2_0351. Panel 1 of each plate contains the blank. Panel 2 of each plate contains SK36. 














































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 3. Biofilm imaging by confocal laser scanning microscopy (CLSM) of 24 mutants that 
have shown to affect biofilm formation through preliminary data. Each WT and mutant was 
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1064-C SK36-C  
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2205-C SK36-C   
  






























































































































































































































































































































69 1363-C SK36-C 
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Figure 4. Biofilm imaging by confocal laser scanning microscopy (CLSM) of mutant selected 









































































































































































Figure 5. Comparison of (A) SK36 and (B) XG2_0351 morphologies using scanning electron 
 














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 10. Quantitative data for confocal images. Relative intensity of biofilm formation 





































































































































Figure 11. Whole protein extraction from bacterial strains SK36 and mutant sample were 
separated by SDS-PAGE and stained with coomassie blue. The arrows indicate possible 



































































































































Oral biofilm formation in streptococci has shown to be involved in a variety of microbial infections in 
the human body, through recruiting diverse bacterial species to site of infection and displaying an effective 
defense system against host immune defenses (Hall, McGillicuddy et al. 2014). Biofilm formation involves 
numerous stages, namely attachment, maturation, and dispersion (Lister, Horswill 2014, Foster, Geoghegan et 
al. 2014). Streptococcus sanguinis has been shown to be involved in biofilm formation (Xu, Alves et al. 2007, 
Kolenbrander, London 1993). Investigating the S. sanguinis genes involved in biofilm formation will be 
indispensable in uncovering potential drug targets against diverse bacterial infections that involve biofilm 
formation in the oral cavity. 
 
A set of 51 non-essential genes (Table 2) was screened previously in our lab for the ability to affect 
biofilm formation using microtiter assay as described by O’Toole (O'Toole 2011). This constituted the starting 
point for the project of studying S. sanguinis genes involved in biofilm formation. Bioinformatically, we 
identified for every biofilm related gene functions using clusters of orthologous groups (COGs) annotations 
(Table 3), as described by Uniprot, as well as operon (and genetic neighbors) and the presence/absence of 
paralogues (using BLAST with identity >70% and E-value cutoff 10
-7
 ) (Table 3). On the wet lab level, we ran 
a microtiter assay with crystal violet (CV) staining to confirm the previous findings, which concurred to a high 
degree to the previous findings. Out of 51 mutants, 25 mutants that exhibited a reduced biofilm formation as 
shown by CV staining (Figure 2) were further investigated using confocal laser scanning microscopy (CLSM). 
The CLSM images, obtained in triplicates from every mutant, showed variant patterns in biofilm reduction 
(Figure 3). 
 
Mutant XG2_0351 was selected for further study in this project based upon results that were obtained 
through crystal violet staining and CLSM images (Figure 4). The biofilm formation of XG2_0351 showed 







conclusively ascertained through CLSM. Contrasting greatly with the biofilm formed by SK36, there was 
essentially no biofilm formation observed in either experiment when the XG2_0351 gene was knocked out. 
Downstream mutant, XG2_0350, was visualized using CLSM to eliminate the possibility of the polar effect 
(Figure 8). Consequently, XG2_0351, one of two signal peptidase I (SPase I) enzymes in S. sanguinis, was 
selected for investigation in this project because of considerable phenotypic differences from SK36, in terms of 
biofilm formation, and also because little information is known about the role that type I signal peptidase plays 
in biofilm formation in this bacterium. Furthermore, even less is known about how SPase I affects biofilm in a 
bacterium with multiple SPase I enzymes. 
 
To further investigate the phenotypic role of XG2_0351 gene on biofilm formation, we used SEM to 
visualize the morphological differences in growth between the SK36 and SPase I mutant, XG2_0351. The 
images (Figure 5) show that the XG2_0351 chains are shorter in length and remain stunted in growth in 
comparison to the long chains formed by the wild type. In bacteria, the cell wall bears the stress and helps 
maintain the shape, and is important for cell viability. The scaffold of the cell wall consists of the cross-linker 
polymer peptidoglycan. Studies have demonstrated that there is a relationship between peptidoglycan synthesis, 
bacterial growth, and cell shape (Scheffers, Pinho 2005). Mutants that lack one or several enzymes involved in 
the synthesis of peptidoglycan or other cell wall components display changes in cell shape. Molecular analyses 
of another member of viridans, S. gordonii, showed that some genes required for biofilm formation are involved 
in peptidoglycan biosynthesis (Loo, Corliss et al. 2000). Therefore, we can conclude that in SK36 the SPase I is 
necessary to cleave proteins which are crucial to maintain cell shape and cell wall, possibly through 
peptidoglycan synthesis. 
 
To gain additional information about the growth disparities between SK36 and XG2_0351, comparison 
of growth curves between wild type and XG2_0351 using a plate reader (Figure 6). The exponential 







pictures depict phenotypic differences in morphology between SK36 and mutant, the growth curves show no 
substantial difference in rate of growth. The OD values remain comparable for both which means that this 
SPase I has demonstrated no substantial role in cell growth. In many bacteria that have been analyzed so far, 
type I signal peptidase has been proven to be essential for cell viability (Sharma, Pradhan et al. 2005, Paetzel, 
Karla et al. 2002, Date 1983, Klug, Jager et al. 1997). For example, E. coli strain IT41 possesses a mutated 
leader peptidase gene, which has a drastically reduced growth rate. The growth rate was reduced because E. coli 
only has one SPase I (Sharma, Pradhan et al. 2005, Inada, Court et al. 1989). In contrast to these findings, S. 
sanguinis does not show a diminished growth rate when this SPase I is knocked out. 
 
Defining the link between XG2_0351 and biofilm formation on a molecular level demands 
characterizing the mechanism of action in details, including substrates of XG2_0351. This is a challenging task 
given the fact that S. sanguinis possesses two type I signal peptidases, namely XG2_0351 and XG2_0849, 
which may share the same pool of substrates. This led to further examination of bacteria that have multiple 
SPases I, a common feature of gram-positive bacteria (Bonnemain, Raynaud et al. 2004). In E. coli the SPase I 
is essential for cell viability but S. sanguinis has proven to sustain life even without this enzyme as seen in 
knockout experiments and growth curves (Figure 6). XG2_0351 is not essential because the other SPase I in S. 
sanguinis, XG2_0849, functionally compensates with respect to cell viability when XG2_0351 is absent. Some 
other types of bacteria that share this characteristic with S. sanguinis are Streptomyces, S. lividans, L. 
monocytogenes, and B. japonicum (Bonnemain, Raynaud et al. 2004). 
 
The largest number of type I signal peptidases in one single species thus far have been found in gram-
positive eubacterium Bacillus subtilis. Five genes that specify type I signal peptidases present on the B. subtilis 
chromosome. Studies have shown that these enzymes, denoted as SipS, SipT, SipU, SipV, and SipW, have 
different but overlapping substrate specificities (Sharma, Pradhan et al. 2005). There are two main advantages 







preference and secondly, a modulation of activity in response to high demands on the secretion machinery 
(Bron, Bolhuis et al. 1998, Bolhuis, Sorokin et al. 1996). Unlike the SPase I in E. coli, SipS was not essential 
for viability of the cell nor for protein secretion. Although in the absence of SipS, the rate of processing of 
several preproteins was reduced (Bolhuis, Sorokin et al. 1996). These sip genes are not essential individually 
but a specific combination of mutations in these genes is lethal (Bron, Bolhuis et al. 1998). It will be intriguing 
to discover if the same scenario will occur in S. sanguinis once both SPase I genes are knocked out. 
 
To gain further clues regarding the molecular mechanism of action of XG2_0351, we searched 
XG2_0351 in the STRING database for protein-protein interaction networks from known metabolic pathways, 
protein complexes, signal transduction pathways, and other carefully selected databases (Figure 7A). The 
information obtained is from experimental data, computational prediction methods, and public text collections. 
Knowledge of protein-protein interactions is essential to understand cellular processes at the system-level. The 
protein-protein interaction network of XG2_0351 visualized by STRING revealed that this SPase I protein 
interacts with several ribosomal proteins. Ribosomal subunits that are involved in the cellular process of 
translation are composed of these proteins and rRNA. This SPase I also interacts with SRPR and SRP54 
proteins which are signal recognition particles involved in targeting and inserting nascent membrane proteins 
into the cytoplasm. One or more SRP protein in conjunction with SRP RNA contributes to the binding and 
release of signal peptide. Then the SPase I proteolytically cleaves them from translocated precursor proteins 
from the extracytoplasmic site of the membrane (Auclair, Bhanu et al. 2012, du Plessis, Nouwen et al. 2011). 
 
Gene co-occurrence visually displayed the gene families whose occurrence patterns across genomes 
show similarities (Figure 7B). For each gene of interest, the color indicates the similarity of its best hit in a 
given STRING genome. The similarities in these presence/absence profiles can predict interactions. Two 
distinct colors indicate the lowest and highest similarity observed within that clade. The highest similarities are 







Firmicutes, has three contiguous SPase I genes called SipX, SipY and SipZ. The major SPase I of L. 
monocytogenes is SipZ because the amounts of extracellular virulence factors such as listeriolysin O, 
phosphatidylcholine C, and zinc metalloproteinase were significantly decreased upon inactivation. For the 
majority of Sec-secreted exoproteins identified, the three SPases I were found to function redundantly. This 
became clear when protein secretion was not affected by the inactivation of only one or two of the SPases I. 
Since the SipZ of L. monocytogenes applies only to a small subset of the secreted exoproteins, the concept of 
minor and major SPases appears to be relative, not absolute (Bonnemain, Raynaud et al. 2004, Renier, Chafsey 
et al. 2015). In order to compare the type I signal peptidases in S. sanguinis, CLSM images of XG2_0351 
paralogue, XG2_0849, were compared to images of SK36. 
 
In order to investigate the potential role of the other SPase I, XG2_0849, in biofilm formation, we 
compared the biofilm formation between S. sanguinis wild type and XG2_0849 using confocal microscopy 
(Figure 9). The CLSM image of XG2_0849 showed a slight difference when assessed against SK36 but not as 
drastically as XG2_0351. There is a possibility that XG2_0351 is responsible for cleaving more biofilm related 
proteins than XG2_0849. The quantitative data obtained by measuring the relative intensities of confocal 
images (Figure 10) clearly illustrated that XG2_0351 biofilm is ten-fold decreased when compared to SK36, 
whereas the downstream mutant (XG2_0350) and parlogue (XG2_0849) were not significantly different from 
the wild type. In S. sanguinis, XG2_0351 appears to be the major SPase I when biofilm formation is concerned. 
This scenario was shown to occur in P. aeruginosa, which has two noncontiguous SPases I. PA1302 is involved 
with quorum-sensing cascade and includes the suppression of virulence factor secretion and virulence-
associated phenotypes, while LepB is the primary SPase (Waite, Rose et al. 2012). 
 
Finally, to narrow the list of potential substrates of XG2_0351 involved in biofilm formation, we 
extracted whole cell proteins from S. sanguinis wild type and compared it to that from XG2_0351 (Figure 11). 







further separated the extracted proteins by SDS-PAGE and stained with Coomassie-Brilliant Blue. Nine 
substrates of SPase I enzyme, XG2_0351, which were previously shown through CV staining (Figure 2) and 
confocal imaging (Figure 3) to exhibit reduced biofilm formation, were absent in XG2_0351 mutant in 
comparison to wild type. These may provide clues about molecular mechanism adopted by XG2_0351 to affect 
biofilm formation and provide a potential drug target with promising impact on reducing biofilm formation. 
 
Further study is necessary to claim that XG2_0351 is to S. sanguinis what SipZ is to L. monocytogenes. 
The predominance of one SPase I over another is a bacterium is dependent on more than biofilm formation 
factors. The major SPase I is essential for efficient protein secretion which is contingent upon the availability of 
SPases, the production levels of secreted proteins, and substrate specificity or substrate preference of the 
different type I SPases (Bolhuis, Sorokin et al. 1996). Coomassie blue staining was done to measure the levels 
of proteins in SK36 and XG2_0351. 
 
This study indicates that type I signal peptidase mutant, XG2_0351, causes a decrease in biofilm 
formation when compared to SK36. This SPase I performs a more critical role in biofilm formation than 
XG2_0849. Gene 0351 is possibly necessary for functions that include but are not limited to cell-wall 
metabolism, collagen-binding, iron transportation, and antibiotic resistance (Table 5 & Figure 11). These 
contribute to the successful formation of biofilm in S. sanguinis. Future studies may further the investigation by 
creating a double knockout mutant of both XG2_0351 and XG2_0849 and measuring cell viability. Pulse-chase 
protein radiolabeling would give a deeper understanding of the activity of proteins over a prolonged period of 
time. Mass spectrometry could be utilized to reveal which proteins are missing in XG2_0351 and therefore, 
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